Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.eurofins.com/cdmo
Number of Employees: 450
Year Founded: 1993
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Eurofins Amatsigroup SAS, a contract development and manufacturing organization, provides drug development and lifecycle management services throughout the preclinical to clinical phase. The company offers drug substance process development and manufacturing for biologics; pharmaceutical analysis solutions, such as fit-for-purpose method developments and validations, stability studies, and quality control; and formulation development and manufacturing of sterile and non-sterile clinical or small commercial batches. It serves biotechnology and mid-size pharmaceutical companies in Europe. Eurofins Amatsigroup SAS was formerly known as Amatsi SAS and changed its name to Eurofins Amatsigroup SAS in August 2013. The company was founded in 1993 and is based in Saint-Gély-du-Fesc, France. As of October 1, 2017, Eurofins Amatsigroup SAS operates as a subsidiary of Eurofins Scientific SE.


Financial Information (Currency: CAD, in mm)
Total Revenue
 25.7
Operating Income
 (0.6)
Total Assets
 41.6
Gross Profit
 24.4
EBITDA
 0.8
Total Debt
 11.2
Net Income
 1.7
Estimated Number of Employees
 450
Net Debt
 11.0
Private Co. Financial Data  as of Dec-31-2022. * Hover over data point numbers for date and source.

Key Professionals
Name
Title
Arnaud, Jean-Pierre 
Chief Executive Officer


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
17 Parc des Vautes | Saint-Gély-du-Fesc, Languedoc-Roussillon | 34980 | France
Phone: 33 4 99 58 38 60   

Parent Company
Eurofins Scientific SE (ENXTPA:ERF)

Prior Investors
Ekkio Capital (Jean-Marc Sceo, Thibaud Gachet), Ekkio Capital II FCPR, Naxicap Partners


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Pharmaceutical and Biotech Services Businesses at Artigues-près-Bordeaux and Martillac
As of August 31, 2017, Pharmaceutical and Biotech Services Businesses at Artigues-près-Bordeaux and Martillac were acquired by Amatsigroup. Pharmaceutical and Biotech Services Businesses at Artigues-près-Bordeaux and Martillac comprises pharmaceutical development operations. The assets are located in France.

Europe
Pharmaceuticals
-
-
-
Disposable-Lab SAS
Disposable-Lab SAS is a contract development (CDO) and a contract manufacturing organization (CMO) that specializes in processing sterile products using its own proprietary disposable technologies. The company was founded in 2008 and is based in Martillac, France. As of January 18, 2017, Disposable-Lab SAS operates as a subsidiary of Amatsigroup.

Europe
Life Sciences Tools and Services
-
-
-
Q-Biologicals NV
Q-Biologicals NV manufactures biological substances with the help of living, biological processes. The company engages in the production and purification of proteins. Q-Biologicals NV was founded in 2011 and is based in Gent, Belgium. As of January 25, 2016, Q-Biologicals NV operates as a subsidiary of Amatsigroup.

Europe
Commodity Chemicals
-
-
-
Pierre Fabre S.A., Pharmaceutical Development Center in Saint-Augustin
As of September 30, 2015, Pierre Fabre S.A., pharmaceutical development center in Saint-Augustin was acquired by Amatsigroup. Pierre Fabre S.A., Pharmaceutical Development Center in Saint-Augustin develops pharmaceutical products. The asset is located in France.

Europe
Pharmaceuticals
-
-
-
SEPS Pharma NV
SEPS Pharma NV, a pharmaceutical company, develops prodrug approaches and drug delivery systems of generic drugs, in-licensed promising compounds, and drugs of which the patent rights are near expiration. The company develops prodrugs, lipophilic prodrugs systems, and self emulsifying prodrug systems in various therapeutic areas, including infectious diseases, oncology, migraine, and chemotherapy-induced and postoperative nausea vomiting. Its pipeline products comprise oral dosage forms of drugs that are currently administered intravenously; and long-acting injectables of drugs, which are currently delivered through daily oral administration. The company also provides product development services, including preclinical, preformulation, liquid and solid formulation, dosage form, analytical, and bioanalytical development services, as well as scaling-up services. SEPS Pharma NV was founded in 2007 and is based in Tongeren, Belgium. As of January 23, 2015, SEPS Pharma NV operates as a subsidiary of AMATSI.

Europe
Biotechnology
-
-
-
Avepharm
As of August 1, 2013, Avepharm was acquired by AMATSI.

Europe
-
-
-
-
D.B.I. SAS
As of August 1, 2013, D.B.I. SAS was acquired by AMATSI.

Europe
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-31-2017
Aug-31-2017
Merger/Acquisition
Buyer
Pharmaceutical and Biotech Services Businesses at Artigues-près-Bordeaux and Martillac
Eurofins Amatsigroup SAS
Bertin Pharma SAS
-
Jul-10-2017
Sep-30-2017
Merger/Acquisition
Target
Eurofins Amatsigroup SAS
Eurofins Scientific SE (ENXTPA:ERF)
Ekkio Capital Seller Funds:Ekkio Capital II FCPR
193.60
Jan-18-2017
Jan-18-2017
Merger/Acquisition
Buyer
Disposable-Lab SAS
Eurofins Amatsigroup SAS

-
Jan-25-2016
Jan-25-2016
Merger/Acquisition
Buyer
Q-Biologicals NV
Eurofins Amatsigroup SAS
Participatiemaatschappij Vlaanderen NV Seller Funds:Vlaams Innovatiefonds
-
Oct-1-2015
Sep-30-2015
Merger/Acquisition
Buyer
Pierre Fabre S.A., Pharmaceutical Development Center in Saint-Augustin
Eurofins Amatsigroup SAS
Pierre Fabre S.A
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-30-2017
M&A Transaction Closings
Eurofins Scientific SE (ENXTPA:ERF) completed the acquisition of Amatsigroup from Ekkio Capital II FCPR, managed by Ekkio Capital and others.
Aug-31-2017
M&A Transaction Closings
Amatsigroup acquired Pharmaceutical and Biotech Services Businesses at Artigues-près-Bordeaux and Martillac from Bertin Pharma SAS.
Jul-10-2017
M&A Transaction Announcements
Eurofins Scientific SE (ENXTPA:ERF) signed an exclusive agreement to acquire Amatsigroup from Ekkio Capital II FCPR, managed by Ekkio Capital and others for €170 million.
Apr-10-2017
Seeking Acquisitions/Investments
Amatsigroup Seeks Acquisitions
Jan-18-2017
M&A Transaction Closings
Amatsigroup acquired Disposable-Lab.

M&A Advisors
CABINET F.L., Deloitte Finance, UGGC & Associés, Willkie Farr & Gallagher LLP, Willkie Farr & Gallagher LLP


Advisors
M&A Advisors
CABINET F.L., Deloitte Finance, UGGC & Associés, Willkie Farr & Gallagher LLP, Willkie Farr & Gallagher LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Oct 17, 2019 04:04 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS
Reports
21
GlobalData

Apr 10, 2019 10:59 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Mar 14, 2019 04:35 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS
Reports
21
GlobalData

Jan 11, 2019 02:53 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
18
GlobalData

Dec 07, 2018 04:03 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS
Reports
20
GlobalData

Dec 05, 2018 05:59 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
18
GlobalData

Sep 20, 2018 07:56 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
18
GlobalData

Sep 18, 2018 07:10 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS
Reports
20
GlobalData

Jun 18, 2018 03:04 AM
Eurofins Amatsigroup SAS
Amatsigroup SAS
Reports
20
GlobalData

Apr 11, 2018 11:20 PM
Eurofins Amatsigroup SAS
Amatsigroup SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
18


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Mar-06-2018
Dec-31-2017
Eurofins Amatsigroup SAS
Company Website
Annual Report
3 MB

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Arnaud, Jean-Pierre 
Chief Executive Officer
33 4 99 58 38 60
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
